BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2285303)

  • 1. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.
    Clarkson AB; Sarić M; Grady RW
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1833-5. PubMed ID: 2285303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia.
    Clarkson AB; Williams DE; Rosenberg C
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1158-63. PubMed ID: 3142346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy.
    Smith D; Davies S; Nelson M; Youle M; Gleeson J; Gazzard B
    AIDS; 1990 Oct; 4(10):1019-21. PubMed ID: 2261116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients.
    Smith DE; Davies S; Smithson J; Harding I; Gazzard BG
    AIDS; 1992 Dec; 6(12):1489-93. PubMed ID: 1492932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects.
    McCann PP; Bacchi CJ; Clarkson AB; Bey P; Sjoerdsma A; Schecter PJ; Walzer PD; Barlow JL
    Am J Trop Med Hyg; 1986 Nov; 35(6):1153-6. PubMed ID: 3098121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.
    Chin K; Merali S; Sarić M; Clarkson AB
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2318-20. PubMed ID: 8891137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of infection due to Pneumocystis carinii.
    Fishman JA
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1309-14. PubMed ID: 9624465
    [No Abstract]   [Full Text] [Related]  

  • 8. Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.
    Merali S; Chin K; Grady RW; Clarkson AB
    Antimicrob Agents Chemother; 1996 May; 40(5):1298-300. PubMed ID: 8723489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.
    Cushion MT; Stanforth D; Linke MJ; Walzer PD
    Antimicrob Agents Chemother; 1985 Dec; 28(6):796-801. PubMed ID: 3936409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome.
    Golden JA; Sjoerdsma A; Santi DV
    West J Med; 1984 Nov; 141(5):613-23. PubMed ID: 6440364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats.
    D'Antonio RG; Johnson DB; Winn RE; van Dellen AF; Evans ME
    Antimicrob Agents Chemother; 1986 Feb; 29(2):327-9. PubMed ID: 3487285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.
    Walzer PD; Kim CK; Foy J; Linke MJ; Cushion MT
    Antimicrob Agents Chemother; 1988 Jun; 32(6):896-905. PubMed ID: 3137861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically achievable plasma deferoxamine concentrations eliminate Pneumocystis carinii trophozoites in a rat model.
    Merali S; Chin K; Grady RW; Clarkson AB
    J Eukaryot Microbiol; 1996; 43(5):52S. PubMed ID: 8822854
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.
    Boylan CJ; Current WL
    Infect Immun; 1992 Apr; 60(4):1589-97. PubMed ID: 1548080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).
    Bartlett MS; Fishman JA; Durkin MM; Queener SF; Smith JW
    Exp Parasitol; 1990 Jan; 70(1):100-6. PubMed ID: 2295322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.
    Merali S; Chin K; Grady RW; Weissberger L; Clarkson AB
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1442-4. PubMed ID: 7492082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.
    Sarić M; Clarkson AB
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2545-52. PubMed ID: 7872745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eflornithine treatment of Pneumocystis carinii pneumonia in AIDS.
    Gilman TM; Paulson YJ; Boylen CT; Heseltine PN; Sharma OP
    JAMA; 1986 Oct 24-31; 256(16):2197-8. PubMed ID: 3093697
    [No Abstract]   [Full Text] [Related]  

  • 19. Action of deferoxamine against Pneumocystis carinii.
    Clarkson AB; Turkel-Parrella D; Williams JH; Chen LC; Gordon T; Merali S
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3560-5. PubMed ID: 11709340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.
    Merali S; Chin K; Del Angel L; Grady RW; Armstrong M; Clarkson AB
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2023-6. PubMed ID: 8540710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.